vobarilizumab (ALX-0061) - Sanofi
Ablynx: Corporate Presentation (Ablynx) - Jun 19, 2015 - Anticipated initiation of P2 trial (NCT02437890) in SLE in mid-2015; Anticipated top-line data from P2 trial (NCT02437890) in SLE in 2018 
Anticipated P2 data • Anticipated trial initiation date Immunology
http://www.ablynx.com/uploads/home/08a0704a-7709-4f62-9a68-c65b4664f0bb-ablynxcorporatepresentation_june2015_website.pdf
 
Jun 19, 2015
 
.
 
09076fd8-0cb3-4c18-8df1-7334c6e6061f.jpg

875400f7-16b6-4212-b4d6-31b2e5ffd863.jpg